SCHEMBL2377020

SCHEMBL2377020

CC1CN(S(C)(=O)=O)CCC1NC(=O)Nc1cnc2c(ccn2COCC[Si](C)(C)C)n1

nearest known ligand 0.43

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 9/20 0.43
JAK3 P52333 8/20 0.43
JAK1 P23458 6/20 0.41
SMYD3 Q9H7B4 11/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2377199 0.95 JAK2 (0.46) JAK2JAK3JAK1
SCHEMBL2378774 0.95 JAK2 (0.45) JAK2JAK3JAK1
SCHEMBL2378224 0.90 JAK2 (0.51) JAK2JAK3JAK1
SCHEMBL2378230 0.90 JAK2 (0.51) JAK2JAK3JAK1
SCHEMBL2378232 0.90 JAK2 (0.51) JAK2JAK3JAK1
SCHEMBL2379346 0.89 JAK2 (0.56) JAK2JAK3JAK1SMYD3
SCHEMBL2378605 0.88 JAK2 (0.41) JAK2JAK3JAK1SMYD3
SCHEMBL2377700 0.88 JAK2 (0.35) JAK2JAK3JAK1SMYD3
SCHEMBL2376192 0.87 JAK2 (0.57) JAK2JAK3JAK1
SCHEMBL2377347 0.87 JAK2 (0.57) JAK2JAK3JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102232076-A Pyrrolopyrazinyl urea kinase inhibitors HOFFMANN LA ROCHE 2011-11-02 CN disclosed
EP-2373653-A1 PYRROLOPYRAZINYL UREA KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-10-12 EP disclosed
US-8012974-B2 Pyrrolopyrazinyl urea kinase inhibitors ROCHE PALO ALTO LLC (US) 2011-09-06 US disclosed
WO-2010063634-A1 PYRROLOPYRAZINYL UREA KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-06-10 WO disclosed
US-20100144745-A1 Pyrrolopyrazinyl Urea Kinase Inhibitors ROCHE PALO ALTO LLC 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144745-A1 Pyrrolopyrazinyl Urea Kinase Inhibitors JAK1, JAK3, ULK3 JAK2 5/4885JAK3 2/4885JAK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.